Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

The Lancet Oncology

Volumn 18, Issue 3, 2017, Pages 312-322

  Sharma, Padmanee ^a   Retz, Margitta ^b   Siefker Radtke, Arlene ^a   Baron, Ari ^c   Necchi, Andrea ^d   Bedke, Jens ^e   Plimack, Elizabeth R ^f   Vaena, Daniel ^g   Grimm, Marc Oliver ^h   Bracarda, Sergio ⁱ   Arranz, José Ángel ^j   Pal, Sumanta ^k   Ohyama, Chikara ^l   Saci, Abdel ^m   Qu, Xiaotao ^m   Lambert, Alexandre ^m   Krishnan, Suba ^m   Azrilevich, Alex ^m   Galsky, Matthew D ⁿ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ IRCCS POLICLINICO SAN DONATO   (Italy)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l HIROSAKI UNIVERSITY   (Japan)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NIVOLUMAB; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DECREASED APPETITE; DETERIORATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC UROTHELIAL CARCINOMA; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEMPHIGOID; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SKIN DISEASE; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR RECURRENCE; UROLOGIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLATINUM; PROGNOSIS; SURVIVAL RATE; UROLOGIC NEOPLASMS;

EID: 85010904121     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30065-7     Document Type: Article

References (29)

1. 1 Bellmunt, J, von der Maase, H, Mead, GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30 (2012), 1107–1113.
2. 2 Von der Maase, H, Hansen, SW, Roberts, JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000), 3068–3077.
3. 3 Sonpavde, G, Galsky, MD, Latini, D, Chen, GJ, Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer 12 (2014), 71–73.
4. 4 Galsky, MD, Hahn, NM, Rosenberg, J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29 (2011), 2432–2438.
5. 5 Ortmann, CA, Mazhar, D, Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol 9 (2013), 1637–1651.
6. 6 Raggi, D, Miceli, R, Sonpavde, G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27 (2016), 49–61.
7. 7 Boorjian, SA, Sheinin, Y, Crispen, PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14 (2008), 4800–4808.
8. 8 Faraj, SF, Munari, E, Guner, G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 85 (2015), 703–706.
9. 9 Inman, BA, Sebo, TJ, Frigola, X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109 (2007), 1499–1505.
10. 10 Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
11. 11 Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
12. 12 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
13. 13 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
14. 14 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
15. 15 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
16. 16 Sharma, P, Callahan, MK, Bono, P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm phase 1/2 trial. Lancet Oncol 17 (2016), 1590–1598.
17. 17 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
18. 18 Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
19. 19 Osoba, D, Rodrigues, G, Myles, J, Zee, B, Pater, J, Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998), 139–144.
20. 20 EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
21. 21 Pickard, AS, Neary, MP, Cella, D, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
22. 22 Choi, W, Czerniak, B, Ochoa, A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11 (2014), 400–410.
23. 23 Bellmunt, J, Choueiri, TK, Fougeray, R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28 (2010), 1850–1855.
24. 24 Massard, C, Gordon, MS, Sharma, S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
25. 25 Plimack, ER, Bellmunt, J, Gupta, S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol, 2017 published online Jan 9. http://dx.doi.org/10.1016/S1470-2045(17)30007-4.
26. 26 Choueiri, TK, Ross, RW, Jacobus, S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30 (2012), 507–512.
27. 27 Hainsworth, JD, Meluch, AA, Litchy, S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103 (2005), 2298–2303.
28. 28 Zaretsky, JM, Garcia-Diaz, A, Shin, DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375 (2016), 819–829.
29. 29 Gao, J, Shi, LZ, Zhao, H, et al. Loss of IFN-γ signaling in tumor cells as a mechanism of primary resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404.